Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 78.7%

Neg 0% Neu 0% Pos 78.7%

Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $17 to $30.